These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 11264165)

  • 1. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
    Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
    Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
    Kano Y; Akutsu M; Tsunoda S; Mano H; Sato Y; Honma Y; Furukawa Y
    Blood; 2001 Apr; 97(7):1999-2007. PubMed ID: 11264164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
    Weisberg E; Griffin JD
    Blood; 2000 Jun; 95(11):3498-505. PubMed ID: 10828035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
    Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
    J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
    Deutsch E; Maggiorella L; Wen B; Bonnet ML; Khanfir K; Frascogna V; Turhan AG; Bourhis J
    Br J Cancer; 2004 Nov; 91(9):1735-41. PubMed ID: 15494718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
    Thiesing JT; Ohno-Jones S; Kolibaba KS; Druker BJ
    Blood; 2000 Nov; 96(9):3195-9. PubMed ID: 11050003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
    Wertheim JA; Forsythe K; Druker BJ; Hammer D; Boettiger D; Pear WS
    Blood; 2002 Jun; 99(11):4122-30. PubMed ID: 12010816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
    J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
    Nakajima A; Tauchi T; Ohyashiki K
    Leukemia; 2001 Jun; 15(6):989-90. PubMed ID: 11417489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.